Product

Bortezomib + Dexamethasone / Bortezomib + Dexamethasone + Daratumumab / single Daratumumab

1 clinical trial

1 indication

Indication

Immunoglobulin Light-chain Amyloidosis

Clinical trial

Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis: A Randomized Controlled Trial

Status: Not yet recruiting, Estimated PCD: 2026-03-31